Nemifitide vs Rapastinel: Peptide Antidepressants with Rapid Onset

Introduction#

Nemifitide and rapastinel represent two attempts to develop peptide-based antidepressants with rapid onset of action -- a goal that has become increasingly important given that conventional antidepressants (SSRIs, SNRIs) typically require 4-6 weeks for therapeutic effect. Both peptides showed promising rapid antidepressant effects in early clinical studies, and both ultimately failed to achieve regulatory approval, albeit for different reasons and at different stages.

Rapastinel (GLYX-13) was developed by Allergan and received FDA Breakthrough Therapy designation for treatment-resistant depression based on its NMDA receptor-modulating mechanism -- convergent with ketamine but without dissociative side effects. It failed all three pivotal phase 3 trials in 2019. Nemifitide (INN-00835) was developed by Innapharma/Tetragenex and showed rapid onset in multiple early-phase studies, but its clinical development program never reached a definitive phase 3 conclusion.

Their parallel stories illuminate both the promise and the challenges of developing novel rapid-acting antidepressants.

Mechanism of Action Comparison#

Nemifitide#

Nemifitide (INN-00835) is a synthetic pentapeptide with the sequence 4-F-Phe-4-OH-Pro-Arg-Gly-Trp-NH2, structurally related to melanocyte-inhibiting factor (MIF-1). Its mechanism of action is not fully elucidated:

• Multi-receptor binding: Binds to 5-HT2A (serotonin receptor, as an antagonist), NPY1 (neuropeptide Y receptor), bombesin receptors, and MC4/MC5 (melanocortin receptors) at micromolar concentrations
• Blood-brain barrier penetration: Crosses the BBB despite being a peptide, enabling central effects
• Very short half-life: Plasma half-life of only 15-30 minutes, yet antidepressant effects persist for weeks
• Structural relationship: Related to MIF-1 and other small peptides with documented CNS activity, but the precise mechanism linking its multi-receptor binding to antidepressant effects remains unclear

The disconnect between nemifitide's very short half-life and its sustained clinical effects suggests it may trigger a cascade of downstream neuroplastic changes rather than requiring continuous receptor occupancy.

Rapastinel#

Rapastinel (GLYX-13, threonyl-prolyl-prolyl-threonyl-NH2) is an amidated tetrapeptide that modulates the NMDA receptor:

• Glycine site partial agonist: Enhances NMDA receptor activity at the glycine modulatory site without the excessive activation or blockade associated with ketamine
• Synaptic plasticity: Enhances the magnitude of long-term potentiation (LTP) at excitatory synapses in the medial prefrontal cortex and hippocampus
• BDNF/mTOR signaling: Promotes BDNF release and activates mTOR signaling, mechanisms shared with ketamine's rapid antidepressant effects
• Metaplasticity: Produces long-lasting antidepressant effects through metaplasticity -- changes in the capacity for future synaptic plasticity -- rather than simple acute receptor modulation
• No dissociative effects: Unlike ketamine (an NMDA antagonist), rapastinel does not produce dissociation, psychotomimetic effects, or cognitive impairment

Mechanistic Comparison#

Dosing Comparison#

Nemifitide Dosing#

Based on clinical trial protocols:

• Route: Subcutaneous injection (inactive orally)
• Phase 2 doses: 30 mg/day and 45 mg/day studied in RCT
• Frequency: Daily injection during treatment periods, though sustained effects from infrequent dosing observed
• Onset: 48 hours to peak effect at approximately 1 week
• Duration of effect: Efficacy sustained during 4-week follow-up periods after treatment cessation

Rapastinel Dosing#

Based on clinical trial protocols:

• Route: Intravenous infusion
• Phase 2 dose: Single IV dose of 1, 5, 10, or 30 mg/kg studied
• Efficacious dose: 5 and 10 mg/kg showed significant antidepressant effects in phase 2
• Frequency: Single dose or weekly IV infusions
• Onset: Within 24 hours of single IV administration
• Duration of effect: Antidepressant effects sustained for 7+ days after single dose

Side Effects Comparison#

Nemifitide Side Effects#

Remarkably well tolerated across clinical studies:

• No consistent side effects: Published studies report "few to no side effects" in over 430 patients across 12 clinical trials
• No serious adverse events: No serious adverse events consistently attributed to nemifitide
• Short systemic exposure: The 15-30 minute half-life means minimal sustained systemic exposure
• No withdrawal effects: No evidence of dependence or withdrawal
• No sexual dysfunction: Unlike SSRIs, no sexual side effects reported

Rapastinel Side Effects#

Also well tolerated, with a clean separation from ketamine's side effects:

• No dissociation: Unlike ketamine, rapastinel did not produce dissociative symptoms
• No psychotomimetic effects: No hallucinations, perceptual disturbances, or psychosis
• No cognitive impairment: No acute cognitive impairment or memory disruption
• No abuse potential: No evidence of reinforcing effects or addiction liability
• Common adverse events: Mild and transient -- headache, dizziness, and somnolence most reported
• No respiratory depression: Unlike ketamine, no respiratory concerns

Research Evidence Comparison#

Nemifitide Research#

• Phase 1/PK studies: Established pharmacokinetic profile and demonstrated BBB penetration and subcutaneous bioavailability
• Open-label studies: Showed rapid onset (48 hours) with peak effect at approximately 1 week. Efficacy sustained for 4+ weeks after treatment cessation
• Phase 2 RCT: 30 mg/d and 45 mg/d compared to placebo in major depressive disorder. Results described as mixed, with some evidence of efficacy but not uniformly positive
• Treatment-refractory study: Open-label study in severely depressed, treatment-refractory patients showed meaningful response
• Re-treatment: Follow-up re-treatment study showed comparable or improved response compared to initial treatment
• Overall: 12 clinical studies, 430+ patients. Never completed a definitive phase 3 program

Evidence level: Low -- multiple phase 1/2 studies with intriguing results, but no definitive phase 3 RCT. Mixed controlled trial results.

Rapastinel Research#

• Phase 2 (Preskorn et al., 2015): Single IV dose of rapastinel (1, 5, 10, or 30 mg/kg) as adjunctive therapy showed significant antidepressant effects at 5 and 10 mg/kg within 24 hours, sustained for 7+ days
• FDA designations: Fast Track (2014) and Breakthrough Therapy (2016) designations based on phase 2 data
• Phase 3 failure (2019): All three pivotal phase 3 trials failed to differentiate rapastinel from placebo on primary and key secondary endpoints
• OCD proof of concept: Small study showed potential benefit in obsessive-compulsive disorder
• PTSD potential: Preclinical data suggested efficacy in PTSD models
• Legacy: Spurred development of next-generation NMDA modulators including apimostinel (NRX-1074) and zelquistinel (AGN-241751), an oral compound

Evidence level: Low -- promising phase 2 data but definitive phase 3 failure. Development discontinued by Allergan.

Key Differences Summary#

• Mechanism: Nemifitide has a poorly understood multi-receptor mechanism. Rapastinel has a well-characterized NMDA glycine site mechanism.
• Clinical stage: Nemifitide completed multiple phase 1/2 studies but never had a definitive phase 3. Rapastinel reached and failed phase 3.
• Administration: Nemifitide uses subcutaneous injection. Rapastinel requires IV infusion.
• FDA recognition: Rapastinel received Fast Track and Breakthrough Therapy designations. Nemifitide received no FDA designations.
• Onset: Both showed rapid onset (nemifitide 48 hours, rapastinel 24 hours), dramatically faster than conventional antidepressants.
• Tolerability: Both were remarkably well tolerated with no significant or dose-limiting adverse effects in clinical trials.
• Development status: Both are effectively discontinued. Rapastinel's mechanism inspired next-generation compounds.

Conclusion#

Nemifitide and rapastinel share a common narrative: rapid-acting peptide antidepressants with excellent tolerability that ultimately could not demonstrate reliable efficacy in definitive clinical trials. Both showed genuine promise in early-phase studies, suggesting that peptide-based approaches to depression can achieve rapid onset without the side effects that limit existing rapid-acting treatments (ketamine, esketamine).

Rapastinel's story is more instructive because its well-characterized mechanism and phase 3 program provide clearer lessons. The phase 3 failure was attributed primarily to unusually high placebo response rates -- a well-known challenge in depression clinical trials -- rather than to a fundamental flaw in the NMDA modulation approach. Its mechanism has been validated by the success of ketamine/esketamine and continues to be pursued through next-generation oral compounds.

Nemifitide's story is more enigmatic. Its multi-receptor binding, very short half-life with sustained effects, and limited but intriguing clinical data raise questions that were never fully answered by a definitive trial program. The mechanistic basis for its antidepressant activity remains unclear.

Both peptides contributed to the growing understanding that rapid-acting antidepressant mechanisms exist beyond monoamine modulation, and that peptide-based approaches can achieve central nervous system effects with favorable safety profiles. Their failures underscore the difficulty of translating early-phase antidepressant promise into phase 3 success.

Further Reading#

• Nemifitide Overview and Research Guide
• Nemifitide Side Effects
• Nemifitide Dosing Protocols
• Rapastinel Overview and Research Guide
• Rapastinel Side Effects
• Rapastinel Dosing Protocols